AstraZeneca PLC (AZN)
After hours:
| Previous close | 75.80 |
| Open | 76.47 |
| Bid | 76.34 x 500 |
| Ask | 76.40 x 500 |
| Day's range | 75.43 - 76.49 |
| 52-week range | 60.47 - 76.80 |
| Volume | |
| Avg. volume | 6,513,403 |
| Market cap | 236.783B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 37.81 |
| EPS (TTM) | 2.02 |
| Earnings date | 25 July 2024 |
| Forward dividend & yield | 1.45 (1.90%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | 81.91 |
ZacksTop Analyst Reports for AstraZeneca, QUALCOMM & FedEx
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX).
ZacksAmgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
Business WireCALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
WILMINGTON, Del., May 02, 2024--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL).
